In a controlled, randomized, double-blind study we investigated the long-term effects of the PI -adrenoceptor agonist prenalterol in 16 patients with severe congestive heart failure (NYHA class III or IV). Previous to and 1 week, 3 months, and 6 months after continuous oral intake of 40 to 120 mg prenalterol a day, catheterization of the right heart combined with an ergometer test was carried out; M mode and two-dimensional echocardiograms as well as systolic time intervals were also recorded. With prenalterol the heart rate increased within 1 week from 81 ± 7 to 90 ± 7 beats/min (mean ± SD) (p < .05) and remained increased after 3 months (93 + 9 beats/min, p < .01) and 6 months (91 + 6 beats/min, p < .05). After 1 week the cardiac index rose from 2.7 + 0.7 to 3.3 + 0.7 1/min/m2 (p < .01), and after 3 and 6 months it fell again to 3.0 ± 0.9 1/min/m2 and 2.9 ± 0.7 1/min/ m2, respectively. In the ergometer test the improvement in performance was not significant. The mean velocity of circumferential fiber shortening initially increased from 0.58 + 0.20 to 0.79 ± 0.28 circumferences/sec (p < .01), but dropped after 3 months to 0.62 ± 0.31 circumferences/sec. The ejection fraction determined from the two-dimensional echocardiogram rose after 1 week from 20 + 10 to 27 + 12% (p < .05), but decreased again after 3 months (23 + 11%) and 6 months (20 ± 10%). Initially, the end-diastolic pressure of the pulmonary artery decreased from 24 ± 5 to 21 ± 6 mm Hg (p < .05), but rose again after 3 months to 23 + 6 mm Hg and after 6 months to 23 ± 4 mm Hg. After 1 week, the index for duration of the mechanical systole decreased by 3.8 + 2.3% (p < .001), but after 3 and 6 months such an improvement was no longer evident. The results indicate that prenalterol is not an effective drug for the treatment of patients with heart failure, because its effects are not sustained during long-term administration. Circulation 69, No. 2, 298-305, 1984. IN PATIENTS whose severe congestive heart failure cannot be sufficiently compensated with cardiac glycosides, diuretics, or vasodilators, the administration of a positive inotropic drug should be considered.iA The ,f3-adrenoceptor agonist prenalterol (the left isomeric form of S-(-)-1-(4-hydroxyphenoxy)-3-isopropylamino-2-propranolol-hydrochloride) can be given both intravenously and orally. In animal studies5 and clinical investigations, this substance was shown to have aB,/stimulating property.-'7 It was the aim of this controlled, randomized, double-blind study to test the long-term effects after oral administration of prenalterol.
Patients. The investigations were carried out in 16 patients (11 men and five women, 53 + 7 years old). Twelve patients had congestive heart failure and were in functional class III according to the classification of the New York Heart Association (NYHA) and four were in functional class IV (table 1). All patients underwent catheterization of the right and left heart before being included in the study. Eleven patients suffered from a dilated cardiomyopathy and five had severe ischemic heart disease. Patients 2, 3, 10, 1 17 and 13 were patients 9, 4, 8, 2, and 3 in our previous hemodynamic study. 2 Procedure. The patients were randomized into two groups of eight (figure 1). During a run-in period of 1 week, both groups were given placebos. Thereafter, prenalterol was given orally to the first group in a double-blind manner for 3 months, while the second group received placebos over the same period. The preparations of prenalterol and placebos were produced and coded by A. B. Haessle, Sweden. After 3 months the code was opened, and all patients in both groups were treated with prenaterol for another 3 months. For the duration of the study, the basic medication with cardiac glycosides, diuretics, and isosorbide dinitrate was continued. The serum digoxin levels were within the therapeutic range (1.7 to 2.4 nmol/l, mean 2.1).
During the last 2 days of the run-in period, clinical data were collected in the coronary care unit and a rhythm analysis was carried out over 18 hr by computer analysis of the electrocardiogram. Thereafter, all patients remained hospitalized in the coro-CIRCULATION BSA = body surface area; COCM = dilated cardiomyopathy; IHD = ischemic heart disease; LAD = left anterior descending coronary artery; LCx = left circumflex coronary artery; NYHA = New York Heart Association; RCA = right coronary artery; Dig = digitalis; Spir = spironolactone; Fur = furosemide; ISDN = isosorbide dinitrate; Mex = mexiletine; TMT = triamterene. nary care unit for 1 week during which the test substance was given under continuous monitoring of the electrocardiogram. On the second day the patients received an oral dose of 20 mg of the test substance, and on the following day they received two doses of 20 mg. The dose was increased daily by 10 mg until a distinct subjective improvement in the patients was observed or until a heart of 100 beats/min was reached. At the end of the stabilization period the dose was 40 to 120 mg/day (mean 71 ± 21) and was administered unaltered for 6 months. The patients were examined clinically and electrocardiographically as outpatients at monthly intervals. The subjective complaints and the objective clinical findings of the examination were recorded. Patient 5 had to be hospitalized after 4 months because of an increase in left ventricular failure. At this point the treatment with prenalterol was discontinued. After 4.5 months patient 6 unexpectedly died at home of sudden heart failure. A postmortem examination was not carried out.
Measurements. Before the administration of the test substance and after 1 week, 3 months, and 6 months, catheterization of the right heart combined with an ergometer test was carried out, and the one-and two-dimensional echocardiograms as well as the systolic time intervals were recorded. The recordings were performed for all patients at the same time during a steady state 4 to 5 hr after oral intake of the test substance. After 1 week, 3 months, and 6 months, right atrial pressure, pulmonary artery pressure, and the cardiac output were ascertained with a Swan-Ganz catheter, while the arterial blood pressure was measured with a sphygmomanometer. The derived hemodynamic parameters were calculated as follows: CI = CO/ Vol. 69, No The end-diastolic and end-systolic left ventricular diameters were measured in five consecutive cardiac cycles, and the percent of fiber shortening and the mean velocity of the circumferential fiber shortening (VCf) were calculated. 7a
The systolic time intervals were recorded with a chart speed of 100 mm/sec. The values for duration of the mechanical systole (QS2), preejection period of the left ventricle (PEP), and the left ventricular ejection time (LVET) were obtained from five consecutive cardiac cycles.'18 The influence of the heart rate on the systolic time intervals was eliminated with the regression equation of Weissler.'9
In the rectangular tolerance test a uniform comparable increase was selected by means of an electromagnetically braked bicycle ergometer with the patient in a lying position.20 Starting with 20 W the load was increased at intervals of 1 min by 10 until the maximum load was reached. The electrocardiogram was continuously recorded for the duration of the exercise test. Criteria for discontinuing the test were dyspnea and/or fatigue.
"Work-pulse" was calculated as follows: workload (watts) x 60 J/beat heart rate (beats/min) The plasma levels of prenalterol were determined by means of gas chromatography after 1 week, 3 months, and 6 months. 21 The plasma was stored (deep-frozen at -180 C) until the time of the analysis.
The statistical calculations were performed with the Wilcoxon rank test for pair differences. In simultaneous statistical comparisons between the prenalterol group and the control group, the Mann-Whitney U test was used. A value of p < .05 was taken to be statistically significant.
Results
Clinical findings. After 1 week of treatment with prenalterol, five out of eight patients claimed there was a distinct subjective improvement sufficient to. place them in the next NYHA functional class, and after 3 months this improvement was still felt by two patients (figure 2). After 4 months of treatment with prenalterol, patient 5 was hospitalized again due to increased left ventricular failure and had to be excluded from the study. Patient 6 died unexpectedly of sudden heart failure after 4.5 months. After 3 months of treatment with prenalterol, five out of 16 patients improved by one NYHA class.
However, since spontaneous improvement also occurred in the placebo-treated group, no significant difference could be observed between the two groups during long-term therapy.
Hemodynamic findings. With prenalterol (table 2) the heart rate rose after 1 week from 81 + 7 to 90 + 7 beats/min (p < .05). Even after 3 and 6 months there was evidence that the chronotropic effect persisted, with rates of 93 + 9 beats/min (p < .01) and 91 ± 6 beats/min (p < .05), respectively. In the control group the heart rate remained constant during the first 3 months, but after the patients were treated with prenalterol it rose during the following 3 months from 86 ± 9 to 92 + 12 beats/min (p < .05). After 1 week of treatment with prenalterol, the cardiac index rose from 2.7 + 0.7 to 3.3 0.7 1/min/m2 (p < .01), after 3 months it was 3.0 0.9 1/min/M2 (not significant), and after 6 months it was 2.9 0.7 1/min/m2 (not significant). In the control group the cardiac index remained unchanged for the first 3 months, but after treatment with prenalterol it rose from the third until the sixth month from 2.4 ± 0.5 to 2.8 + 0.6 1/min/M2 (p < .05). After 1 week of treatment with prenalterol, the stroke volume index rose from 33 + 8 to 37 ± 7 ml/m2 (p < .05), but fell again after 3 months to 32 7 ml/m2 and after 6 months to 31 ± 9 MIl/m2. The changes of the stroke work index are shown in figure 3. Changes in mean arterial pressure were not significant in either group. After 1 week of treatment with prenalterol, the arterial resistance dropped by 192 dyn-seccm-5 (p < .05), and after 3 months it was 60 dyn-seccm-5 above the initial value.
Echocardiographic findings. The two groups of patients did not differ significantly from one another with CIRCULATION As in the control group the changes were no longer significant after 3 and 6 months. The index for PEP was reduced after 1 week of treatment with prenalterol from 166 ± 19 to 152 ± 13 msec (not significant). ASystolic time intervals obtained before and after 1 week, 3 months, and 6 months of treatment with prenalterol. Bp < .01. combination with vasodilators, may clearly improve left ventricular function.3'4' 22, 23 Since up to now sympathomimetics could only be administered intravenously,' 24 the orally absorbable substance prenalterol was developed for long-term treatment. In short-term studies a clear improvement in the systolic and diastolic function of the left ventricle could be demonstrated after intravenous administration of prenalterol.i'7 However, the changes were dependent on the initial hemodynamic condition. 12 In all our patients the hemo-
Maximum
Work-pulse Increase in PA-mean workload SBP (watts) (joules/beat) ( dynamic and echocardiographic findings were decidedly poor. The congestive heart failure of the patients could not be sufficiently compensated with cardiac glycosides, diuretics, and vasodilators. Prenalterol has a distinct positive chronotropic effect that is not only evident after intravenous administration, but persists for the whole 6 months of oral therapy.10' 11, 13, 15 The heart rate of 100 beats/min was only exceeded in one patient who initially had tachycardia. In all patients in the prenalterol group a distinct hemodynamic response to the sympathomimetic amine could be seen after 1 week of therapy as an increase in the stroke work index and a decrease in the end-diastolic pulmonary arterial pressure.25 Our results are in concordance with the findings of a 22% increase in the cardiac index after intravenous administration of 5 to 15 mg prenalterol. 7 10, 26 With an increase in performance of 9.7 ± 4.3 W in the ergometer test after 1 week, the discrete yet parallel rise in the work-pulse points towards the positive inotropic effect of prenalterol. This improvement in left ventricular function was, however, only temporary, and the exercise data must be interpreted as showing no evidence of a persisting long-term effect. After 3 and 6 months, deterioration could again be shown by use of the systolic time intervals and by use of the hemodynamic and echocardiographic parameters. In the control group there was no significant deterioration of the hemodynamic parameters during the 3 months of therapy with cardiac glycosides, APlasma levels of prenalterol after oral intake after 1 week, 3 months, and 6 months.
BFor patient 7 the initial dose of 80 mg was reduced to 40 mg after 2 months of treatment because of arrhythmias. diuretics, and isosorbide dinitrate alone, suggesting that the spontaneous course of the disease is quite stable (table 2).28-31 After 3 months the two groups did not differ significantly from one another with regard to hemodynamic and echocardiographic parameters. In the systolic time intervals the decrease in QS2I is also a sign of the positive inotropic stimulation32 and the PEP/LVET quotient reflects the overall hemodynamic changes.32' 3 After 6 months the reduction of QS2J indicated a sustained drug effect in two patients.
It was impossible to draw a dose-response relationship for prenalterol on the basis of the plasma levels of prenalterol and on the data from hemodynamic measurement. The variation in the initial hemodynamic conditions of the different patients appears to be responsible for this.
None of the patients complained of angina pectoris during the administration of prenalterol. However, during the titration period, ventricular arrhythmias were temporarily observed in four out of eight patients between the second and fourth day of treatment, but they were no longer apparent after the fifth day. The appearance of ventricular arrhythmias during treatment with prenalterol have been reported.34 In the control group an increase in arrhythmias could not be observed. It was mainly the patients in NYHA class IV who, from the start, benefited only moderately from the treatment with prenalterol. It could be established both on the basis of their subjective statements and on the hemodynamic measurements obtained that after 3 or 6 months of therapy with prenalterol, a lasting improvement in their condition could not be achieved. A possible detrimental effect must even be discussed. Generally in patients with severe congestive heart failure, highly elevated plasma levels of catecholamines are found whereby the extent of elevation is in direct relation to the ventricular dysfunction.'3 [35] [36] [37] [38] The development of tolerance after long-term administration of ,82-selective sympathomimetic amines has already been reported.339 40 Different authors were able to demonstrate that during treatment with /-adrenoceptor agonists, a reversible agonist-induced decrease in P3receptors occurs, which is the cause of development of tolerance.4143 The persisting positive chronotropic effect of prenalterol for 6 months and the decrease in heart rate after clearance of the medication seem to indicate that such an effect does not exist for this drug. 34' 44 There was little difference between patients treated with prenalterol and those treated with placebos, suggesting an extremely limited role for this drug in the treatment of patients with congestive heart failure.
